GlaxoSmithKline PLC ADR (GSK)vsRobinhood Markets Inc (HOOD)
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
HOOD
Robinhood Markets Inc
$77.03
+0.98%
FINANCIAL SERVICES · Cap: $68.69B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 611% more annual revenue ($32.78B vs $4.61B). HOOD leads profitability with a 41.1% profit margin vs 17.8%. GSK trades at a lower P/E of 13.1x. GSK earns a higher WallStSmart Score of 66/100 (B-).
GSK
Strong Buy66
out of 100
Grade: B-
HOOD
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Intrinsic value data unavailable for HOOD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 38.5%
Large-cap with strong market position
Every $100 of equity generates 22 in profit
15.1% revenue growth
Generating 1.2B in free cash flow
Areas to Watch
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Premium valuation, high expectations priced in
2.7% earnings growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : HOOD
The strongest argument for HOOD centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 41.1% and operating margin at 38.5%. Revenue growth of 15.1% demonstrates continued momentum.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Bear Case : HOOD
The primary concerns for HOOD are P/E Ratio, EPS Growth, Debt/Equity. Debt-to-equity of 1.68 is elevated, increasing financial risk.
Key Dynamics to Monitor
GSK profiles as a value stock while HOOD is a growth play — different risk/reward profiles.
HOOD carries more volatility with a beta of 2.29 — expect wider price swings.
HOOD is growing revenue faster at 15.1% — sustainability is the question.
HOOD generates stronger free cash flow (1.2B), providing more financial flexibility.
Bottom Line
GSK scores higher overall (66/100 vs 56/100), backed by strong 17.8% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Robinhood Markets Inc
FINANCIAL SERVICES · CAPITAL MARKETS · USA
Robinhood Markets Inc (HOOD) is a pioneering fintech company that has transformed the retail investing landscape since its inception in 2013 by providing a commission-free trading platform accessible via an intuitive mobile app. The firm caters to a diverse user base, allowing access to a wide array of investment vehicles, including stocks, ETFs, options, and cryptocurrencies, while prioritizing financial literacy and inclusivity. By offering innovative features such as fractional shares and cash management solutions, Robinhood positions itself as a key player in the digital brokerage sector, appealing to a new generation of investors seeking efficient and transparent ways to engage with financial markets.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?